US first-line indication for Novartis's Tasigna in CML
This article was originally published in Scrip
Executive Summary
Novartis's tyrosine kinase inhibitor Tasigna (nilotinib), a follow-on to Gleevec/Glivec (imatinib), has been approved by the US FDA for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase following a priority review.